| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -1.58M | -1.58M | 68.00K | 449.00K | -103.00K | -59.00K |
| Gross Profit | -1.66M | -1.66M | -1.70M | 441.00K | -111.00K | -76.00K |
| EBITDA | -2.62M | -1.75M | -1.88M | 381.00K | -160.00K | 0.00 |
| Net Income | 54.81M | -1.75M | -1.88M | 381.00K | -160.00K | -110.00K |
Balance Sheet | ||||||
| Total Assets | 7.47M | 7.47M | 9.21M | 1.73M | 1.34M | 1.49M |
| Cash, Cash Equivalents and Short-Term Investments | 139.00K | 139.00K | 292.00K | 184.00K | 211.00K | 270.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 93.00K | 93.00K | 84.00K | 24.00K | 15.00K | 11.00K |
| Stockholders Equity | 7.38M | 7.38M | 9.13M | 1.70M | 1.32M | 1.48M |
Cash Flow | ||||||
| Free Cash Flow | -235.50K | -157.00K | -210.00K | -70.00K | -59.00K | -71.00K |
| Operating Cash Flow | -235.50K | -157.00K | -210.00K | -70.00K | -59.00K | -71.00K |
| Investing Cash Flow | 6.00K | 4.00K | 52.00K | 68.00K | 0.00 | 295.00K |
| Financing Cash Flow | 0.00 | 0.00 | 266.00K | -25.00K | 0.00 | -80.00K |
Oxford Technology 2 VCT Plc reported its third-quarter results for 2025, highlighting a slight decrease in net asset value for some share classes due to changes in the valuations of its principal AIM-quoted investments, Scancell Holdings Plc and Arecor Therapeutics Plc. Despite positive developments such as Arecor’s FDA feedback and co-development agreement, and Scancell’s promising trial results, both companies faced market challenges, with minimal share price increases. The company’s unquoted investments remained stable, and no significant changes in share transactions or dividends were reported.
Oxford Technology 2 VCT Plc announced the successful passing of all resolutions at its Annual General Meeting on October 7, 2025, with proxy votes representing 24.5% of the issued share capital. The meeting also marked the retirement of David Livesley, who served the company for 21 years, contributing significantly to its growth and development. This announcement is now public under the UK Market Abuse Regulation.